Ozempic · DIN 02540258 · 0.68 mg/mL · injection solution - pre-filled pen 3mL Pk
Limited Use, Reason for Use code 667 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 667 required
Write on scriptReason for Use code 667 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 667
Reason for Use code 667
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02540258
Manufacturer: Novo Nordisk Canada Inc; listing date 2024-01-31
Health Canada: Marketed since 2023-12-22 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 0.68 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
Ministry pays: $78.1410 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540258)
Source record
DIN 02540258: Ozempic
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006009; group id 759; item number 1864; lccId 00382; manufacturer id NOO
Source form: Inj Sol - Pref Pen 3mL Pk; strength: 0.68mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $227.9400; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540258
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102895
Interchangeable products
Apo-Semaglutide Injection · DIN 02568020 · $78.1410
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02540258
Shortage record checked October 6, 2026